For many people paying out of pocket, the cost of semaglutide has been the biggest barrier to starting treatment. The good news is that pricing has changed dramatically over the past year. Manufacturer self-pay programs, lower monthly prices, new oral options, and a temporary Medicare program have all made FDA-approved semaglutide more accessible than it was even a year ago. Understanding how these options work can help you have a more informed conversation with a licensed provider about what fits your budget.
What Semaglutide Costs Without Insurance in 2026
Semaglutide is the active ingredient in several FDA-approved prescription medications made by Novo Nordisk. Wegovy is approved for chronic weight management, while Ozempic is approved for adults with type 2 diabetes. Both are now available as a weekly injection or a daily pill, and Novo Nordisk sells each directly to self-pay patients at a flat monthly price. The table below summarizes current self-pay pricing as published by the manufacturer.
| FDA-Approved Semaglutide Option | Current Self-Pay Price (Per Month) | Key Details |
|---|---|---|
| Wegovy® injection (weekly pen, for chronic weight management) | $349 | Same price across the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. Eligible new patients may pay $199 per month for their first two fills of the 0.25 mg and 0.5 mg doses through December 31, 2026. |
| Wegovy® HD injection (7.2 mg) | $399 | Higher strength pen with its own flat monthly self-pay price. |
| Wegovy® pill (daily tablet, for chronic weight management) | $149 to $299 | $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg. |
| Ozempic® injection (weekly pen, for type 2 diabetes) | $349 to $499 | $349 for the 0.25 mg, 0.5 mg, and 1 mg doses and $499 for the 2 mg dose. A $199 introductory price for the first two fills is available to eligible new patients through December 31, 2026. |
| Ozempic® pill (daily tablet, for type 2 diabetes, formerly Rybelsus®) | $149 to $299 | Monthly price depends on the prescribed strength. |
Prices reflect Novo Nordisk self-pay pricing as of September 2026 and may change at any time. Eligibility requirements and program restrictions apply.
List Price vs. Self-Pay Price
You may still see much higher figures quoted online. Those numbers usually refer to the list price, which is the price set before insurance negotiations and discounts. The current list price is roughly $1,349 per month for Wegovy and about $1,028 per month for Ozempic. Novo Nordisk has announced that it will lower the list price of Wegovy, Ozempic, and its oral semaglutide tablets to $675 per month starting January 1, 2027. For most people without insurance, however, the self-pay price in the table above is the more meaningful number, since it is what you would actually pay through the manufacturer program.
What Affects the Price You Will Pay
Several factors can influence your final monthly cost. The form of medication matters, since the daily pills generally carry lower self-pay prices than the weekly pens at lower strengths. Your prescribed dose also plays a role for some options, such as the 2 mg Ozempic pen or the higher strength Wegovy pills. Where you fill your prescription matters too, because self-pay pricing is available through NovoCare Pharmacy home delivery as well as participating retail pharmacies and partners. Finally, your diagnosis affects which medication is appropriate for you, since Wegovy and Ozempic are approved for different uses.
Manufacturer Savings Programs
Novo Nordisk offers several programs that can reduce what you pay. If you have commercial insurance that covers your medication, a savings offer may lower your copay to as little as $25 per month, with a maximum savings of $100 per month. People enrolled in government health plans are not eligible for this copay offer.
If you are paying entirely out of pocket, the self-pay prices listed above apply, including the introductory $199 pricing for the first two fills when eligible. For people with limited income and no insurance, the Novo Nordisk Patient Assistance Program may provide certain medications at no cost to those who qualify.
New Medicare Option for Weight Management
For people with Medicare Part D, a temporary federal program that began July 1, 2026 allows eligible beneficiaries to access certain weight management medications, including the Wegovy pen and pill, for a flat $50 monthly copay. Eligibility is generally based on BMI and related health conditions, and the program is currently scheduled to run through December 31, 2027. If you have Medicare, it is worth asking your provider and plan whether you qualify.
Other Ways People Manage the Cost
Beyond manufacturer programs, many people use funds from a Health Savings Account (HSA) or Flexible Spending Account (FSA) to cover prescription costs, which allows them to pay with pre-tax dollars. It also helps to plan for the long term, since semaglutide is typically prescribed as an ongoing treatment. Reviewing your budget for continued therapy, rather than just the first few months, can help you choose an option you can realistically maintain.
Working with a Provider to Find an Affordable Path
A licensed healthcare provider can help you sort through these options and determine whether semaglutide is appropriate for you. During a consultation, a provider can review your health history, discuss whether a pill or injection may better fit your needs and budget, and explain which savings programs you may be eligible for. Any prescription decision is made by the provider based on your individual medical needs.
Having an open conversation about your goals and your budget is the best way to build a plan that is safe and sustainable. Heally connects you with licensed providers who can walk you through your options for semaglutide and help you understand what may be right for you. Schedule a consultation with Heally today.
Sources
- NovoCare (Novo Nordisk): Wegovy® Self-Pay Pricing and Savings
- NovoCare (Novo Nordisk): Ozempic® Self-Pay Pricing
- NovoCare (Novo Nordisk): Savings Offer Program for Wegovy®
- Novo Nordisk: Announcement of US List Price Reduction for Semaglutide Medicines
- Novo Nordisk: Patient Assistance Program (PAP)
- NPR: Medicare Launches Weight Loss Drug Option with $50 Copay
- FDA Label: OZEMPIC (Semaglutide Injection) Prescribing Information
- FDA Label: WEGOVY (Semaglutide Injection) Prescribing Information
Important Medical Information and Disclaimers
MEDICAL DISCLAIMER
This information is for educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation. Semaglutide is the active ingredient in FDA-approved prescription medications including Ozempic (injection and pill, the pill formerly marketed as Rybelsus), approved for improving blood sugar control in adults with type 2 diabetes, and Wegovy (injection and pill), approved for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition. Although these medications contain semaglutide, they are approved for different uses and have different dosing schedules. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment plan.
INDIVIDUAL RESULTS VARY
Outcomes with semaglutide treatment vary from person to person. Clinical trial data may not reflect typical real-world experiences. A variety of factors can affect your results, including medication adherence, lifestyle habits such as diet and exercise, metabolic differences, other health conditions, and concurrent medications. No specific result is guaranteed.
IMPORTANT SAFETY INFORMATION
Common side effects of semaglutide may include: Nausea, Vomiting, Diarrhea, Constipation, Stomach pain, Decreased appetite, Indigestion, Belching or gas, Injection site reactions
These side effects are often mild and may lessen over time. Always inform your healthcare provider about any medical conditions, allergies, and all medications you are currently taking before starting semaglutide. Ongoing monitoring is recommended during treatment.
WARNING: Semaglutide has a boxed warning about the potential risk of thyroid C-cell tumors. Do not use this medication if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
FDA ADVERSE EVENT REPORTING
You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA).
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Adverse events may also be reported directly to the manufacturer.
